Israel - Inggeris - Ministry of Health

a.l. medi-market ltd. - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg / 1 ml - irinotecan - irinotecan hcl seacross is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer. irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - bumetanide, quantity: 1 mg - tablet, uncoated - excipient ingredients: agar; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone; polysorbate 80; magnesium stearate; purified talc - burinex is indicated for the treatment of oedema, particularly that associated with congestive heart failure, hepatic and renal diseases including the nephrotic syndrome and acute pulmonary oedema.

Israel - Inggeris - Ministry of Health

rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 30 mg - pyridostigmine - pyridostigmine - pyridostigmine belongs to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.

Israel - Inggeris - Ministry of Health

rafa laboratories ltd - pyridostigmine bromide - tablets - pyridostigmine bromide 60 mg - pyridostigmine - pyridostigmine - pyridostigmine belons to the cholinesterase inhibitor group and is indicated for the treatment of myasthenia gravis.

Israel - Inggeris - Ministry of Health

taro pharmaceutical industries ltd - triamcinolone - tablets - triamcinolone 4 mg - triamcinolone - triamcinolone - rheumatology: - active phases of systemic vasculitis: panarteritis nodosa (in patients with concomitant positive hepatitis b serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (pmr), pmr with giant cell arteritis, arteritis temporalis with acute visual loss;- active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (nsaids) cannot be used:spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- reactive forms of arthritis;- arthritis in sarcoidosis;- severe systemic form of juvenile idiopathic arthritis (still’s disease) or with iridocyclitis refractory to topical treatment.pulmonary and respiratory tract disorders: - bronchial asthma:for the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- chronic obstructive pulmonary disease (copd):for short-term treatment (max. 14 days) of exacerbations;- upper respiratory tract disorders:for short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.dermatology: - oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.nephrology: - minimal change glomerulonephritis;- extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- idiopathic retroperitoneal fibrosis.

Israel - Inggeris - Ministry of Health

eldan electronic instruments co ltd, israel - mannitol - solution for infusion - mannitol 200 mg/ml - mannitol - mannitol 20%, solution for infusion is indicated for: - the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; - the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; - the reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances

Armenia - Inggeris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

troikaa pharmaceuticals ltd - isoflurane - liquid for inhalation - 100%

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - suxamethonium chloride dihydrate, quantity: 100 mg - injection, solution - excipient ingredients: water for injections - for the production of skeletal muscle relaxation in anaesthesia. suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

janssen-cilag international nv - fentanyl hydrochloride - pain, postoperative - analgesics - management of acute moderate to severe post-operative pain for use in a hospital setting only

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - melaleuca oil -